I’m sorry I’ve become too used to working in the pharma industry, where calendars fill up with unnecessary meetings when an email would do fine. As a consultant, I’m used to having a LOT of meetings to review research findings and actionable insights, but the industry’s culture is one of its most significant weaknesses. This is an edited email I received from someone I met in Cambridge. Amy has an MBA from MIT with a minor in pre-med. It shows an industry in deep trouble.